Skip to main content
Premium Trial:

Request an Annual Quote

CollabRx, Alacris Partner on Cancer Sequencing Project

NEW YORK (GenomeWeb News) – CollabRx, a San Francisco-based personalized cancer research services firm, today said that it has initiated a cancer sequencing project in collaboration with Alacris Pharmaceuticals.

The company said that the firms will work together on the TREAT 1000 project, which will sequence 1,000 genomes of people with cancer. It said that the project will "create a compendium of cancer genome information that will inform future research and treatment."

CollabRx has been piloting its CollabRx One services program over the past year. The program uses a variety of genomic technologies for gene expression, SNP analysis, and copy number variation to analyze biopsies of tumors. The firm then uses bioinformatics and systems biology methods to link specific cancers to relevant therapies, thereby providing physicians with information they can use to tailor a treatment plan to individual patients.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.